This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Related articles  • Similar articles in this journal  Topic Collections  • Neurology, Other  • Alert me on articles by topic

Should All Be Made Available?

Vladimir Hachinski, MD, DSc

Arch Neurol. 2000;57:275.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

INCREASINGLY we are forced to choose between the ideal and the affordable. Both Pierre-Louis and Bergen agree that a physician should begin with first-generation drugs in the treatment of epilepsy, but they differ in what should be available among the second-generation drugs. Pierre-Louis wants all drugs to be available, while Bergen wants them selected on the basis of cost-effectiveness studies.

While as a group, second-generation antiepileptics tend to have more specific sites of action and fewer adverse effects, it is not certain that they are more effective. The only certainty is that they are more costly. But they cannot be judged by cost alone. As Bergen points out, although the recently approved fosphenytoin is 100 times more expensive than generic phenytoin, studies suggest that it is worth the price in terms of treatment of complications.

Although in principle all AEDs should be available, in practice that . . . [Full Text of this Article]

London, Ontario

RELATED ARTICLES

New Drugs: Which Should Be Included in the Formulary?: Epilepsy: All New Drugs Should Be Included
Serge J. C. Pierre-Louis
Arch Neurol. 2000;57(2):272-273.
EXTRACT | FULL TEXT  

Restrictions on the Availability of Antiepileptic Drugs
Donna C. Bergen
Arch Neurol. 2000;57(2):273-275.
EXTRACT | FULL TEXT